293 related articles for article (PubMed ID: 32479120)
1. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
Donini M; Buti S; Massari F; Mollica V; Rizzo A; Montironi R; Bersanelli M; Santoni M
Expert Rev Anticancer Ther; 2020 Jun; 20(6):491-501. PubMed ID: 32479120
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
3. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen QN; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
Lancet Oncol; 2024 May; 25(5):e193-e204. PubMed ID: 38697165
[TBL] [Abstract][Full Text] [Related]
4. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
5. State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma.
Dason S; Lacuna K; Hannan R; Singer EA; Runcie K
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390038. PubMed ID: 37253211
[TBL] [Abstract][Full Text] [Related]
6. Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era.
Francolini G; Campi R; Ciccarese C;
Curr Opin Urol; 2024 Jul; 34(4):300-306. PubMed ID: 38595192
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Metastatic Renal Cell Carcinoma].
Richter I; Dvořák J
Klin Onkol; 2018; 31(2):110-116. PubMed ID: 29708353
[TBL] [Abstract][Full Text] [Related]
8. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
10. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
[TBL] [Abstract][Full Text] [Related]
11. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
12. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
14. Multimodal treatment of advanced renal cancer in 2017.
Mennitto A; Verzoni E; Grassi P; Ratta R; Fucà G; Procopio G
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1395-1402. PubMed ID: 28956645
[TBL] [Abstract][Full Text] [Related]
15. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
16. Radiation in the Treatment of Oligometastatic and Oligoprogressive Disease: Rationale, Recent Data, and Research Questions.
Zayed S; Correa RJM; Palma DA
Cancer J; 2020; 26(2):156-165. PubMed ID: 32205541
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Salabert L; Sionneau B; Cochin V; Ravaud A; Gross-Goupil M
Bull Cancer; 2018 Dec; 105 Suppl 3():S221-S228. PubMed ID: 30595150
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.
All S; Garant A; Hannan R
Semin Radiat Oncol; 2021 Jul; 31(3):227-234. PubMed ID: 34090649
[TBL] [Abstract][Full Text] [Related]
19. Treating patients with renal cell carcinoma and bone metastases.
Guida A; Escudier B; Albiges L
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1135-1143. PubMed ID: 30183421
[TBL] [Abstract][Full Text] [Related]
20. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R
Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]